CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
133 hedge funds and large institutions have $555M invested in CTI BioPharma Corp. (DE) Common Stock in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 44 reducing their positions, and 12 closing their positions.
125% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 12
12% more funds holding
Funds holding: 119 → 133 (+14)
9% more capital invested
Capital invested by funds: $510M → $555M (+$44.6M)
9% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 44
19% less call options, than puts
Call options by funds: $5.83M | Put options by funds: $7.21M
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$24.3M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$12.4M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$10.2M |
| 4 |
Millennium Management
New York
|
+$9.88M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$27.2M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$13.4M |
| 3 |
Two Sigma Investments
New York
|
-$7.5M |
| 4 |
LPC
Lion Point Capital
New York
|
-$6.86M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$5.25M |
CTIC Hedge Fund Activity: Q3 2022 in Review
133 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2022, worth a combined $555M — up 8.7% from $510M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CTIC positions and 12 closed out — a net gain of 15 holders — while 48 added to existing stakes and 44 trimmed.
The largest buyer was State Street, adding an estimated $24.3M. The largest seller was NEA Management Company, cutting an estimated $27.2M.
- 133 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2022, up from 119 in Q2 2022.
- Funds reported $555M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2022, up 8.7% quarter-over-quarter.
- 27 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2022 and 12 closed out, a net change of +15 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2022 was State Street, an estimated $24.3M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2022 was NEA Management Company, an estimated $27.2M sold.
Based on aggregated 13F filings for Q3 2022.